William Soliman, PhD

Multiple pharma companies have already announced plans to invest in domestic projects.

As drug prices in the US fluctuate, pharma companies may look to other regions for opportunity.

Pharma companies have the choice of facing strict tariffs or negotiating with the current administration.

A look at the rise of prior authorization certified specialists (PACS)—and their value in improving patient access and outcomes.

A focus on medical affairs and medical science liaisons.